CircADARB1 serves as a new biomarker in natural killer T-cell lymphoma and a potential regulator of p-Stat3

Mei Mei(Zunyi Medical University), Mingzhi Zhang(Soochow University)

Cancer Cell International

November 4, 2021

10.1186/s12935-021-02296-x

Cited by 9

Related Papers

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2013|246

Paracrine and epigenetic control of CAF-induced metastasis: the role of HOTAIR stimulated by TGF-ß1 secretion

|Molecular Cancer|2018|216

A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma

|Journal of Hematology & Oncology|2020|50

Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma

|Nature Communications|2019|34

<p>Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-&gamma;-associated JAK-STAT pathway</p>

|OncoTargets and Therapy|2019|31